Navigation Links
Treating gum disease improves vascular health in Indigenous Australians: Study

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

The study findings may be of particular importance to Aboriginal Australians, who in general have poorer oral health and higher rates of cardiovascular disease.

Published in the latest issue of Hypertension, the study reports a significant decline in thickening of the wall of the carotid artery a year after a single session of gum treatment.

"The study shows that non-surgical periodontal therapy significantly reduced the progression of thickening of the carotid artery over a one-year period," says study co-author, University of Sydney vascular disease expert Dr Michael Skilton.

"The magnitude of the reduction in thickening of the carotid artery in the treatment group, relative to the control group, is similar to what has been observed in other clinical trials in high risk populations.

"The effect is comparable to a 30 per cent fall in low-density lipoprotein cholesterol commonly referred to as 'bad' cholesterol which is associated with a decreased risk of heart disease.

"It's also equivalent to the effects of reversing four years of aging, 8 kg/m2 lower body mass index, or 25 mm Hg lower systolic blood pressure."

The study was prompted by conjecture about the causative relationship between periodontal (gum) disease and atherosclerotic vascular disease and is among the first using a randomised trial to investigate a periodontal intervention on atherosclerotic disease.

Periodontal disease is an inflammatory disease affecting the soft and hard structures that support the teeth. In its early stage, the gums become swollen and red due to inflammation, which is the body's natural response to the presence of harmful bacteria.

In the more serious form of periodontal disease (periodontitis), the gums pull away from the tooth and supporting gum tissues are destroyed. Bone can be lost, and the teeth may loosen or eventually fall out.

Atherosclerosis is the most common cause of heart attacks, strokes, and peripheral vascular disease collectively known as 'cardiovascular disease'. It usually causes no symptoms until middle or older age but as narrowing and hardening of the arteries accelerates, they choke blood flow, causing pain and other serious cardiovascular complications.

Despite reducing thickening of the carotid artery, the study found no effect of periodontal therapy on arterial stiffness another pre-clinical marker of atherosclerotic vascular disease and risk factor for cardiovascular disease.

"Future studies may tell us whether a more intensive approach to periodontal therapy, including regular periodontal maintenance schedules, can produce more marked improvements in vascular structure," Dr Skilton says.

"The findings indicate that periodontal therapy has a systemic impact beyond treating gum disease.

"If further studies can confirm our report the treatment of periodontal disease may become reducing means by which to reduce the risk of cardiovascular disease, especially in high risk populations such as Indigenous Australians."


Contact: Dan Gaffney
University of Sydney

Related medicine news :

1. Methadone programs can be key in educating, treating HCV patients
2. Researchers propose treating prison population to fight US hepatitis C epidemic
3. Extended-release medication offers promise for treating alcohol, opioid dependence
4. Widely used drug no more effective than FDA approved medication in treating epileptic seizures
5. Study unveils new approach to treating brittle bone disease
6. Vibrating capsule shows promising results in treating chronic constipation
7. Treating depression in PD patients: New research
8. CU researchers discover target for treating dengue fever
9. New study confirms benefits of treating heart attack patients with a cheap drug
10. Scientists find potential target for treating mitochondrial disorders
11. Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: